Compare Neurocrine Biosciences Inc (NBIX) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Vanguard Value Index Fund ETF — how do they compare? Neurocrine Biosciences Inc trades at $156.87 (market cap $16.46B), while Vanguard Value Index Fund ETF trades at $226.46. The key difference: Vanguard Value Index Fund ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | VTV | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | — |
52-Week High | $185.50 | $225.35 |
52-Week Low | $123.10 | $179.43 |
Enterprise Value | $16.48B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $156.95, down 4.83% in the last session, with a bearish technical signal from moving averages and ADX. The stock shows strong fundamentals, including a 39% year-over-year revenue growth in Q2 2026 to $959 million and a net income margin of 20.91% for 2026. Recent developments include positive INGREZZA clinical data and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.
The outlook for NBIX is positive with a consensus price target of $208.82, implying 33% upside, supported by robust earnings beats and portfolio expansion. Risks include drug safety issues, competitive pressures, and reliance on INGREZZA sales. Investors should weigh strong analyst bullishness against regulatory and execution risks in the biopharmaceutical sector.
Vanguard Value ETF (VTV) trades at $226.09, up 0.48% with bullish technical signals from moving averages. The ETF focuses on large-cap value stocks and has gained attention for outperforming growth counterparts in 2026, with one Vanguard deep-value fund reportedly up 22% year-to-date according to 247 Wallst on August 10, 2026. Recent institutional activity shows mixed positioning with some firms reducing stakes while others increased holdings.
The outlook remains positive as value strategies gain traction amid tech sector volatility. Key risks include concentration in value stocks and market rotation patterns. Institutional interest persists despite some profit-taking, suggesting continued confidence in the value premium.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
